Dexamethasone for Inpatients With COVID-19 in a National Cohort.

ABSTRACT:

Importance

Limited effective therapeutics are available to hospitalized patients with COVID-19. Clinical trials and observational studies have shown varying effects of systemic corticosteroids, including dexamethasone, in hospitalized patients with COVID-19, with limited descriptions of important patient subgroups.

Objective

To examine the clinical use of dexamethasone for hospitalized patients with COVID-19 respiratory illness and to explore the heterogeneity of treatment outcomes across different subgroups.

Design, setting, and participants

This is a retrospective, propensity score-weighted cohort study of adult patients hospitalized for at least 48 hours for COVID-19 respiratory illness between July 1, 2020, and October 31, 2021, at a large health care network of 1

SUBMITTER: Mourad A 

PROVIDER: S-EPMC10111178 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature